Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation
- PMID: 16266983
- DOI: 10.1158/0008-5472.CAN-05-0422
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation
Abstract
Up to 30% of patients with acute myeloid leukemia (AML) harbor internal tandem duplications (ITD) within the FLT3 gene, encoding a receptor tyrosine kinase. These mutations induce constitutive tyrosine kinase activity in the absence of the natural Flt3 ligand and confer growth factor independence, increased proliferation, and survival to myeloid precursor cells. The signaling pathways and downstream nuclear targets mediating leukemic transformation are only partly identified. Here, we show that the presence of Flt3-ITD constitutively activates Akt (PKB), a key serine-threonine kinase within the phosphatidylinositol 3-kinase pathway. Constitutive activation of Akt phosphorylated and inhibited the transcription factor Foxo3a. Restored Foxo3a activity reversed Flt3-ITD-mediated growth properties and dominant-negative Akt prevented Flt3-ITD-mediated cytokine independence. Conditional Akt activation targeted to the cell membrane induced cytokine-independent survival, cell cycle progression, and proliferation. Importantly, Akt activation was sufficient to cause in vitro transformation of 32D myeloid progenitor cells and in vivo promoted the development of a leukemia-like myeloid disease. Akt phosphorylation was found in myeloid blasts of 86% of AML patients, suggesting an important role in leukemogenesis. In summary, Akt is necessary for increased survival, proliferation, and leukemic transformation by Flt3-ITD, possibly by inactivation of Foxo transcription factors. These findings indicate that Akt and Foxo transcription factors are attractive targets for therapeutic intervention in AML.
Similar articles
-
FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.Oncogene. 2004 Apr 22;23(19):3338-49. doi: 10.1038/sj.onc.1207456. Oncogene. 2004. PMID: 14981546
-
RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.Blood. 2005 Mar 1;105(5):2107-14. doi: 10.1182/blood-2004-03-0940. Epub 2004 Nov 9. Blood. 2005. PMID: 15536149
-
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.Blood. 2000 Dec 1;96(12):3907-14. Blood. 2000. PMID: 11090077
-
NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML.Exp Hematol. 2016 Dec;44(12):1113-1122. doi: 10.1016/j.exphem.2016.08.008. Epub 2016 Sep 22. Exp Hematol. 2016. PMID: 27666490 Review.
-
Role of FLT3 in leukemia.Curr Opin Hematol. 2002 Jul;9(4):274-81. doi: 10.1097/00062752-200207000-00003. Curr Opin Hematol. 2002. PMID: 12042700 Review.
Cited by
-
Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside.Front Cell Dev Biol. 2022 Aug 5;10:944760. doi: 10.3389/fcell.2022.944760. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35990601 Free PMC article. Review.
-
A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication.Diagn Pathol. 2022 Jan 26;17(1):14. doi: 10.1186/s13000-022-01202-x. Diagn Pathol. 2022. PMID: 35081962 Free PMC article.
-
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.Clin Cancer Res. 2014 Apr 15;20(8):2226-35. doi: 10.1158/1078-0432.CCR-13-1978. Epub 2014 Feb 28. Clin Cancer Res. 2014. PMID: 24583795 Free PMC article. Clinical Trial.
-
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.Oncotarget. 2017 Jan 24;8(4):6341-6352. doi: 10.18632/oncotarget.13856. Oncotarget. 2017. PMID: 27974676 Free PMC article.
-
GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways.Oncotarget. 2016 Jul 28;8(50):87002-87015. doi: 10.18632/oncotarget.10881. eCollection 2017 Oct 20. Oncotarget. 2016. PMID: 29152059 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous